Navigation Links
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
Date:2/26/2009

e patients receiving second-line therapies generally have a poorer prognosis than patients in the first-line setting."

About the Report

Renal Cell Carcinoma (Metastatic): Axitinib's Improvements in Overall Survival will Differentiate it from Current and Emerging Therapies is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2
'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
2. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
3. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
4. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
5. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
6. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
7. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today announced that Robert ... Directors. "Bob is an ardent champion for innovation ... privilege to have him on Edwards, board as we pursue ... Edwards, chairman and CEO.  "Bob has provided a valuable perspective ...
(Date:7/30/2015)... (NYSE: RMD ) today announced results for its ... was $453.1 million, a 9 percent increase compared with ... increase on a constant currency basis).  Net income was ... 2014.  Diluted earnings per share for the quarter were ... The results for the quarter ended ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... /CNW/ - The weight loss medication Xenical,(orlistat 120mg) ... as blood pressure, glycaemic,control and lipid profile in ... hypertension, according to a study analysis,presented at the ... analysis strengthens the wealth of data already established,for ...
... BETHESDA, Md., April 23, 2007--A part of the ... ),is thinner in youth with a risk gene ... at the National Institute of Mental,Health (NIMH), one ... A thinner entorhinal cortex, a structure in the ...
Cached Medicine Technology:New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6Cortex Area Thinner in Youth with Alzheimers-Related Gene 2Cortex Area Thinner in Youth with Alzheimers-Related Gene 3Cortex Area Thinner in Youth with Alzheimers-Related Gene 4
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... Back packs ... in a school, however, back packs can wreck havoc on a kid's spine. With ... their supplies to and from school. Make sure you are aware of how to ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, ... small business donation to kick off the campaign for healing and Well-Being. , BeverlyD ... a complete line of raw, organic hair care products, as well as her book, ...
(Date:7/31/2015)... ... , ... When the weather turned hot and warm-season turfgrasses, such as zoysia ... Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names are ... type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure Time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s ... predictive health analytics , Jvion continues to disrupt the predictive analytic and big ... targets patient and population level illness to drive prevention and better health outcomes. ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2
... Abaxis, Inc. (Nasdaq: ABAX ), a ... today that Clint Severson, chairman and chief executive officer, ... New York Emerging Growth Institutional Investor Forum on Tuesday, ... will be held at The Grand Hyatt Hotel in ...
... Best Drugs For Less Magazine Rates 200 MedicationsYONKERS, N.Y., March 17 ... fill their prescriptions: 66% of those polled by Consumer Reports ... they picked it up at the pharmacy counter, while just 4% ... of a drug. And 28% of Americans told Consumer ...
... Dr. Steve Meadows is one of the few area surgeons performing ... ... (PRWEB) March 17, 2009 -- A breakthrough shoulder surgery is restoring ... in their arm from a damaged rotator cuff, a failed shoulder ...
... Researchers have found that over a 10-year period radiologic ... to a study published in the online edition of ... been previously studied in the pregnant population," said Elizabeth ... Warren Alpert School of Medicine at Brown University and ...
... Inc. has been covering the biologics market for Psoriasis ... series which are syndicated primary research reports based on ... The company is now expanding these offerings in ... which aim to compare self-reported treatment patterns with actual ...
... 16 The leader of the nation,s largest veterans ... a meeting with President Obama today to discuss a ... the treatment of military veterans who have suffered service-connected ... plan to require private insurance carriers to reimburse the ...
Cached Medicine News:Health News:Consumer Reports Poll: 66% of Americans Blindsided by Cost of Drugs; Many Not Taking Needed Medications 2Health News:Consumer Reports Poll: 66% of Americans Blindsided by Cost of Drugs; Many Not Taking Needed Medications 3Health News:Consumer Reports Poll: 66% of Americans Blindsided by Cost of Drugs; Many Not Taking Needed Medications 4Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 3Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 4Health News:Study tracks increasing use of CT on pregnant women 2Health News:BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis 2Health News:The American Legion Strongly Opposed to President's Plan to Charge Wounded Heroes for Treatment 2Health News:The American Legion Strongly Opposed to President's Plan to Charge Wounded Heroes for Treatment 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: